Elaine Urbina
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension | 66 | 2025 | 1234 | 12.880 |
Why?
| Vascular Stiffness | 52 | 2025 | 463 | 12.670 |
Why?
| Blood Pressure | 72 | 2025 | 1711 | 9.890 |
Why?
| Cardiovascular Diseases | 78 | 2025 | 1994 | 9.750 |
Why?
| Diabetes Mellitus, Type 2 | 51 | 2025 | 2428 | 6.260 |
Why?
| Carotid Intima-Media Thickness | 25 | 2024 | 90 | 5.930 |
Why?
| Pulse Wave Analysis | 38 | 2025 | 246 | 5.150 |
Why?
| Blood Pressure Monitoring, Ambulatory | 18 | 2025 | 81 | 5.150 |
Why?
| Adolescent | 169 | 2025 | 20158 | 3.780 |
Why?
| Carotid Arteries | 14 | 2021 | 194 | 3.580 |
Why?
| Blood Pressure Determination | 19 | 2025 | 148 | 3.420 |
Why?
| Obesity | 38 | 2025 | 2859 | 3.400 |
Why?
| Hypertrophy, Left Ventricular | 13 | 2022 | 126 | 3.360 |
Why?
| Atherosclerosis | 15 | 2024 | 403 | 3.280 |
Why?
| Risk Factors | 101 | 2025 | 9696 | 3.040 |
Why?
| Pediatric Obesity | 19 | 2025 | 570 | 2.960 |
Why?
| Diabetes Mellitus, Type 1 | 35 | 2025 | 3625 | 2.910 |
Why?
| Child | 128 | 2025 | 20636 | 2.640 |
Why?
| Young Adult | 91 | 2025 | 12282 | 2.460 |
Why?
| Diabetic Angiopathies | 10 | 2025 | 261 | 2.130 |
Why?
| Body Mass Index | 39 | 2024 | 2260 | 2.100 |
Why?
| Risk Assessment | 23 | 2023 | 3223 | 1.930 |
Why?
| Echocardiography | 17 | 2025 | 623 | 1.920 |
Why?
| Cross-Sectional Studies | 44 | 2025 | 5034 | 1.890 |
Why?
| Dyslipidemias | 9 | 2024 | 176 | 1.890 |
Why?
| Male | 154 | 2025 | 62758 | 1.850 |
Why?
| Heart Rate | 14 | 2022 | 797 | 1.820 |
Why?
| Humans | 217 | 2025 | 128020 | 1.810 |
Why?
| Female | 158 | 2025 | 68017 | 1.780 |
Why?
| Autonomic Nervous System Diseases | 4 | 2022 | 34 | 1.720 |
Why?
| American Heart Association | 17 | 2023 | 296 | 1.560 |
Why?
| Heart Ventricles | 7 | 2019 | 765 | 1.450 |
Why?
| Prevalence | 26 | 2025 | 2541 | 1.400 |
Why?
| Ventricular Function, Left | 8 | 2022 | 524 | 1.370 |
Why?
| United States | 55 | 2024 | 13785 | 1.290 |
Why?
| Adult | 81 | 2025 | 35177 | 1.290 |
Why?
| Obesity, Morbid | 6 | 2020 | 239 | 1.280 |
Why?
| Carotid Artery, Common | 7 | 2021 | 35 | 1.280 |
Why?
| Brachial Artery | 10 | 2024 | 185 | 1.260 |
Why?
| Lipoproteins | 6 | 2023 | 171 | 1.240 |
Why?
| Masked Hypertension | 3 | 2025 | 4 | 1.200 |
Why?
| Practice Guidelines as Topic | 12 | 2021 | 1482 | 1.160 |
Why?
| Cholesterol, LDL | 14 | 2024 | 357 | 1.130 |
Why?
| Adiposity | 5 | 2021 | 504 | 1.090 |
Why?
| Cholesterol | 11 | 2024 | 406 | 1.080 |
Why?
| Ventricular Dysfunction, Left | 5 | 2021 | 383 | 1.080 |
Why?
| Blood Glucose | 9 | 2020 | 2092 | 1.070 |
Why?
| White Coat Hypertension | 3 | 2025 | 7 | 1.060 |
Why?
| Age Factors | 20 | 2020 | 3100 | 1.010 |
Why?
| Triglycerides | 12 | 2024 | 523 | 1.000 |
Why?
| Lipids | 8 | 2024 | 619 | 0.980 |
Why?
| Metabolic Syndrome | 7 | 2019 | 338 | 0.980 |
Why?
| Sodium, Dietary | 2 | 2023 | 37 | 0.960 |
Why?
| Cholesterol, HDL | 8 | 2024 | 203 | 0.930 |
Why?
| Arteries | 4 | 2023 | 261 | 0.850 |
Why?
| Tunica Intima | 8 | 2011 | 80 | 0.850 |
Why?
| Carotid Artery Diseases | 5 | 2017 | 64 | 0.840 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 2025 | 170 | 0.830 |
Why?
| Pediatrics | 3 | 2021 | 1044 | 0.820 |
Why?
| Diabetic Neuropathies | 4 | 2023 | 86 | 0.810 |
Why?
| Asymptomatic Diseases | 3 | 2020 | 83 | 0.800 |
Why?
| September 11 Terrorist Attacks | 3 | 2017 | 31 | 0.800 |
Why?
| Prehypertension | 2 | 2013 | 27 | 0.780 |
Why?
| Tunica Media | 3 | 2011 | 37 | 0.770 |
Why?
| Academies and Institutes | 2 | 2021 | 47 | 0.770 |
Why?
| Atrial Fibrillation | 3 | 2023 | 374 | 0.770 |
Why?
| Mass Screening | 5 | 2019 | 1145 | 0.760 |
Why?
| Systole | 9 | 2024 | 190 | 0.750 |
Why?
| Vascular Resistance | 7 | 2014 | 366 | 0.750 |
Why?
| Biomedical Research | 4 | 2019 | 632 | 0.750 |
Why?
| Autonomic Nervous System | 4 | 2019 | 75 | 0.740 |
Why?
| Muscular Dystrophy, Duchenne | 3 | 2021 | 89 | 0.730 |
Why?
| Vasodilation | 4 | 2017 | 461 | 0.730 |
Why?
| Follow-Up Studies | 16 | 2021 | 4853 | 0.720 |
Why?
| Cardiomyopathies | 2 | 2022 | 335 | 0.720 |
Why?
| Adolescent Health | 1 | 2021 | 39 | 0.700 |
Why?
| Ohio | 9 | 2016 | 153 | 0.700 |
Why?
| Exercise | 5 | 2019 | 1917 | 0.690 |
Why?
| Endothelium, Vascular | 7 | 2018 | 844 | 0.690 |
Why?
| Essential Hypertension | 2 | 2023 | 5 | 0.690 |
Why?
| Diet, Mediterranean | 1 | 2020 | 29 | 0.680 |
Why?
| Nervous System Diseases | 1 | 2023 | 251 | 0.670 |
Why?
| Arteriosclerosis | 3 | 2013 | 88 | 0.670 |
Why?
| Insulin Resistance | 6 | 2022 | 1164 | 0.670 |
Why?
| Preventive Medicine | 1 | 2020 | 41 | 0.660 |
Why?
| Longitudinal Studies | 18 | 2024 | 2706 | 0.660 |
Why?
| Life Style | 4 | 2021 | 459 | 0.620 |
Why?
| Arrhythmias, Cardiac | 2 | 2022 | 314 | 0.580 |
Why?
| Environmental Exposure | 5 | 2021 | 458 | 0.580 |
Why?
| Predictive Value of Tests | 10 | 2024 | 1934 | 0.570 |
Why?
| Program Development | 1 | 2020 | 357 | 0.570 |
Why?
| Case-Control Studies | 12 | 2021 | 3324 | 0.560 |
Why?
| Sex Factors | 14 | 2019 | 1942 | 0.560 |
Why?
| Cardiology | 1 | 2020 | 260 | 0.550 |
Why?
| Accelerometry | 1 | 2017 | 91 | 0.540 |
Why?
| Prospective Studies | 18 | 2024 | 7035 | 0.530 |
Why?
| Elasticity | 4 | 2011 | 198 | 0.520 |
Why?
| Advisory Committees | 2 | 2016 | 214 | 0.510 |
Why?
| Particle Size | 1 | 2017 | 352 | 0.500 |
Why?
| Environmental Pollutants | 2 | 2019 | 142 | 0.500 |
Why?
| Self Report | 2 | 2020 | 796 | 0.500 |
Why?
| Incidence | 13 | 2024 | 2614 | 0.490 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 3 | 0.490 |
Why?
| Prediabetic State | 2 | 2016 | 245 | 0.490 |
Why?
| Anticholesteremic Agents | 3 | 2014 | 146 | 0.480 |
Why?
| Linear Models | 9 | 2021 | 816 | 0.480 |
Why?
| Cohort Studies | 19 | 2024 | 5378 | 0.480 |
Why?
| Overweight | 6 | 2024 | 522 | 0.480 |
Why?
| DNA Methylation | 2 | 2019 | 604 | 0.460 |
Why?
| Polycystic Ovary Syndrome | 1 | 2017 | 163 | 0.460 |
Why?
| Disease Management | 2 | 2019 | 583 | 0.460 |
Why?
| Epigenesis, Genetic | 1 | 2019 | 614 | 0.450 |
Why?
| Health Planning Guidelines | 1 | 2013 | 24 | 0.440 |
Why?
| Vasculitis | 1 | 2014 | 59 | 0.440 |
Why?
| Multivariate Analysis | 6 | 2021 | 1492 | 0.440 |
Why?
| Vascular Remodeling | 1 | 2015 | 181 | 0.440 |
Why?
| Child, Preschool | 23 | 2024 | 10378 | 0.430 |
Why?
| Microvessels | 1 | 2014 | 79 | 0.430 |
Why?
| Peripheral Vascular Diseases | 1 | 2014 | 102 | 0.430 |
Why?
| Heart Diseases | 3 | 2022 | 345 | 0.420 |
Why?
| Fibrosis | 2 | 2021 | 513 | 0.420 |
Why?
| Vascular Diseases | 4 | 2020 | 232 | 0.420 |
Why?
| Observational Studies as Topic | 1 | 2013 | 108 | 0.420 |
Why?
| Diastole | 7 | 2022 | 148 | 0.410 |
Why?
| Hyperlipoproteinemia Type II | 4 | 2021 | 34 | 0.410 |
Why?
| Prognosis | 8 | 2021 | 3766 | 0.410 |
Why?
| Phthalic Acids | 1 | 2013 | 45 | 0.400 |
Why?
| Stroke Volume | 4 | 2022 | 588 | 0.360 |
Why?
| Air Pollutants | 3 | 2021 | 310 | 0.360 |
Why?
| Tuberculosis | 2 | 2024 | 271 | 0.360 |
Why?
| Carotid Artery, Internal | 1 | 2011 | 41 | 0.350 |
Why?
| Myocardium | 2 | 2021 | 967 | 0.350 |
Why?
| Body Weight | 6 | 2021 | 930 | 0.350 |
Why?
| Patient Compliance | 3 | 2024 | 558 | 0.340 |
Why?
| HIV Infections | 2 | 2025 | 2703 | 0.340 |
Why?
| Inflammation | 5 | 2021 | 2646 | 0.340 |
Why?
| Finland | 7 | 2024 | 90 | 0.330 |
Why?
| Adiponectin | 1 | 2012 | 234 | 0.330 |
Why?
| Blood Flow Velocity | 5 | 2014 | 404 | 0.330 |
Why?
| Bariatric Surgery | 3 | 2018 | 192 | 0.330 |
Why?
| Disease Progression | 7 | 2021 | 2598 | 0.330 |
Why?
| Exercise Tolerance | 2 | 2022 | 271 | 0.320 |
Why?
| Biomarkers | 14 | 2025 | 3874 | 0.310 |
Why?
| Heart Failure | 2 | 2022 | 2141 | 0.310 |
Why?
| Early Diagnosis | 2 | 2024 | 234 | 0.310 |
Why?
| Carotid Stenosis | 1 | 2009 | 85 | 0.300 |
Why?
| Air Pollution | 3 | 2021 | 214 | 0.300 |
Why?
| Pulsatile Flow | 4 | 2014 | 59 | 0.290 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2013 | 1356 | 0.290 |
Why?
| Albuminuria | 2 | 2025 | 181 | 0.290 |
Why?
| Heart | 2 | 2023 | 637 | 0.280 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2009 | 253 | 0.280 |
Why?
| Sulfonamides | 2 | 2022 | 494 | 0.280 |
Why?
| Ultrasonography | 8 | 2021 | 708 | 0.280 |
Why?
| Turner Syndrome | 2 | 2020 | 51 | 0.280 |
Why?
| Executive Function | 2 | 2024 | 421 | 0.270 |
Why?
| Lipoproteins, HDL | 3 | 2021 | 85 | 0.270 |
Why?
| Bone Density | 2 | 2021 | 474 | 0.270 |
Why?
| Diagnostic Imaging | 1 | 2009 | 329 | 0.260 |
Why?
| Fluorocarbons | 2 | 2019 | 109 | 0.260 |
Why?
| Coronary Artery Disease | 3 | 2019 | 675 | 0.260 |
Why?
| Australia | 6 | 2024 | 243 | 0.260 |
Why?
| Time Factors | 6 | 2020 | 6479 | 0.260 |
Why?
| Health Promotion | 3 | 2019 | 716 | 0.260 |
Why?
| Aortic Diseases | 2 | 2017 | 114 | 0.240 |
Why?
| Comorbidity | 4 | 2019 | 1537 | 0.240 |
Why?
| Age Distribution | 4 | 2021 | 369 | 0.240 |
Why?
| Renin-Angiotensin System | 1 | 2025 | 79 | 0.230 |
Why?
| Anthropometry | 3 | 2019 | 204 | 0.230 |
Why?
| Age of Onset | 4 | 2021 | 490 | 0.220 |
Why?
| Lipoprotein(a) | 2 | 2022 | 67 | 0.220 |
Why?
| Diabetes Mellitus | 3 | 2018 | 994 | 0.220 |
Why?
| Aorta | 2 | 2017 | 408 | 0.220 |
Why?
| Smoking | 4 | 2024 | 1459 | 0.220 |
Why?
| Femoral Artery | 3 | 2014 | 170 | 0.210 |
Why?
| Latent Tuberculosis | 1 | 2024 | 67 | 0.210 |
Why?
| Research Design | 2 | 2019 | 1034 | 0.200 |
Why?
| Hypoglycemic Agents | 3 | 2020 | 1212 | 0.200 |
Why?
| Magnetic Resonance Imaging | 1 | 2014 | 3371 | 0.200 |
Why?
| Antihypertensive Agents | 3 | 2024 | 481 | 0.200 |
Why?
| Vehicle Emissions | 2 | 2021 | 56 | 0.200 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2021 | 101 | 0.200 |
Why?
| Pilot Projects | 4 | 2022 | 1559 | 0.190 |
Why?
| Heart Arrest, Induced | 1 | 2002 | 31 | 0.190 |
Why?
| Fontan Procedure | 2 | 2021 | 172 | 0.190 |
Why?
| Albumins | 1 | 2022 | 101 | 0.190 |
Why?
| Waist Circumference | 2 | 2019 | 138 | 0.190 |
Why?
| Triage | 1 | 2024 | 205 | 0.190 |
Why?
| Transposition of Great Vessels | 1 | 2002 | 34 | 0.190 |
Why?
| Sphygmomanometers | 3 | 2012 | 9 | 0.190 |
Why?
| Acute-Phase Proteins | 1 | 2021 | 67 | 0.190 |
Why?
| Ventricular Remodeling | 2 | 2021 | 254 | 0.190 |
Why?
| Insulin | 3 | 2020 | 2316 | 0.180 |
Why?
| Women's Health | 3 | 2011 | 361 | 0.180 |
Why?
| Allostasis | 1 | 2021 | 16 | 0.180 |
Why?
| Interdisciplinary Research | 1 | 2021 | 26 | 0.180 |
Why?
| Myocarditis | 1 | 2022 | 98 | 0.180 |
Why?
| Attention | 1 | 2024 | 433 | 0.180 |
Why?
| Sodium | 1 | 2022 | 202 | 0.180 |
Why?
| Atrial Function, Left | 1 | 2020 | 7 | 0.180 |
Why?
| Birth Weight | 1 | 2024 | 499 | 0.180 |
Why?
| Parity | 1 | 2021 | 120 | 0.170 |
Why?
| Forecasting | 2 | 2020 | 355 | 0.170 |
Why?
| Sensitivity and Specificity | 2 | 2024 | 1813 | 0.170 |
Why?
| Quantitative Trait, Heritable | 1 | 2021 | 119 | 0.170 |
Why?
| Sex Distribution | 2 | 2021 | 356 | 0.170 |
Why?
| Middle Aged | 16 | 2024 | 30813 | 0.170 |
Why?
| Precision Medicine | 1 | 2024 | 384 | 0.170 |
Why?
| Creatinine | 1 | 2022 | 478 | 0.170 |
Why?
| Epoprostenol | 1 | 2021 | 134 | 0.170 |
Why?
| Pyrimidines | 2 | 2022 | 446 | 0.170 |
Why?
| Paternal Exposure | 1 | 2019 | 1 | 0.170 |
Why?
| Motivation | 1 | 2024 | 544 | 0.170 |
Why?
| Absorptiometry, Photon | 3 | 2021 | 248 | 0.160 |
Why?
| Cognition | 2 | 2024 | 1104 | 0.160 |
Why?
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 36 | 0.160 |
Why?
| Aging | 2 | 2021 | 1745 | 0.160 |
Why?
| Regional Blood Flow | 2 | 2014 | 457 | 0.160 |
Why?
| Diabetes Complications | 4 | 2023 | 223 | 0.160 |
Why?
| Colorado | 5 | 2015 | 4369 | 0.160 |
Why?
| National Institute of Child Health and Human Development (U.S.) | 1 | 2019 | 9 | 0.160 |
Why?
| Preconception Care | 1 | 2019 | 40 | 0.160 |
Why?
| Smokers | 1 | 2020 | 137 | 0.160 |
Why?
| Cell Adhesion Molecules | 1 | 2020 | 173 | 0.160 |
Why?
| Sugars | 1 | 2019 | 37 | 0.160 |
Why?
| Histone Code | 1 | 2019 | 31 | 0.160 |
Why?
| Dimensional Measurement Accuracy | 1 | 2018 | 13 | 0.150 |
Why?
| Judaism | 1 | 2018 | 2 | 0.150 |
Why?
| Compression Bandages | 1 | 2018 | 6 | 0.150 |
Why?
| Fasting | 1 | 2020 | 264 | 0.150 |
Why?
| Dietary Carbohydrates | 1 | 2019 | 150 | 0.150 |
Why?
| Ischemic Preconditioning | 1 | 2018 | 40 | 0.150 |
Why?
| Retrospective Studies | 10 | 2024 | 14404 | 0.150 |
Why?
| Preventive Health Services | 2 | 2017 | 145 | 0.150 |
Why?
| Maternal Exposure | 1 | 2019 | 175 | 0.140 |
Why?
| Cognitive Dysfunction | 2 | 2023 | 343 | 0.140 |
Why?
| ROC Curve | 1 | 2019 | 500 | 0.140 |
Why?
| Nutrition Surveys | 2 | 2024 | 261 | 0.140 |
Why?
| Sleep Apnea, Obstructive | 1 | 2021 | 238 | 0.140 |
Why?
| Bone and Bones | 1 | 2020 | 298 | 0.140 |
Why?
| Guidelines as Topic | 1 | 2019 | 260 | 0.140 |
Why?
| Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.140 |
Why?
| Genetic Predisposition to Disease | 3 | 2021 | 2261 | 0.130 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 68 | 0.130 |
Why?
| Phenotype | 1 | 2025 | 3039 | 0.130 |
Why?
| Myocardial Infarction | 1 | 2024 | 1013 | 0.130 |
Why?
| Morbidity | 2 | 2014 | 301 | 0.130 |
Why?
| Hypolipidemic Agents | 2 | 2007 | 92 | 0.130 |
Why?
| Benzhydryl Compounds | 1 | 2017 | 66 | 0.130 |
Why?
| Risk | 1 | 2019 | 850 | 0.130 |
Why?
| Cardiac Surgical Procedures | 1 | 2002 | 493 | 0.130 |
Why?
| Body Size | 1 | 2017 | 100 | 0.130 |
Why?
| Population Surveillance | 1 | 2019 | 426 | 0.130 |
Why?
| Reference Values | 4 | 2021 | 776 | 0.130 |
Why?
| Consensus | 1 | 2019 | 607 | 0.130 |
Why?
| Adolescent Behavior | 3 | 2020 | 505 | 0.130 |
Why?
| Phenols | 1 | 2017 | 97 | 0.130 |
Why?
| Cytokines | 2 | 2021 | 1984 | 0.130 |
Why?
| School Health Services | 1 | 2019 | 232 | 0.130 |
Why?
| Smoking Cessation | 1 | 2020 | 407 | 0.130 |
Why?
| Memory, Short-Term | 1 | 2018 | 256 | 0.120 |
Why?
| Schools | 1 | 2019 | 436 | 0.120 |
Why?
| MicroRNAs | 2 | 2019 | 674 | 0.120 |
Why?
| Diet Therapy | 1 | 2015 | 34 | 0.120 |
Why?
| Referral and Consultation | 1 | 2020 | 724 | 0.120 |
Why?
| Sleep Wake Disorders | 1 | 2018 | 248 | 0.120 |
Why?
| Ankle Brachial Index | 1 | 2015 | 36 | 0.120 |
Why?
| Chemical Industry | 1 | 2014 | 11 | 0.120 |
Why?
| Petroleum | 1 | 2014 | 8 | 0.120 |
Why?
| Infant, Newborn | 4 | 2024 | 5688 | 0.120 |
Why?
| Health Behavior | 2 | 2020 | 740 | 0.120 |
Why?
| Polycyclic Aromatic Hydrocarbons | 1 | 2014 | 27 | 0.120 |
Why?
| Tachycardia | 1 | 2014 | 56 | 0.120 |
Why?
| Cardiac Output | 1 | 2015 | 154 | 0.110 |
Why?
| Chi-Square Distribution | 1 | 2015 | 511 | 0.110 |
Why?
| Arm | 2 | 2018 | 106 | 0.110 |
Why?
| Electrocardiography, Ambulatory | 1 | 2014 | 57 | 0.110 |
Why?
| Laser-Doppler Flowmetry | 1 | 2014 | 33 | 0.110 |
Why?
| Heart Defects, Congenital | 1 | 2021 | 747 | 0.110 |
Why?
| Forearm | 1 | 2014 | 117 | 0.110 |
Why?
| Oxidative Stress | 2 | 2018 | 1181 | 0.110 |
Why?
| Diabetic Cardiomyopathies | 1 | 2014 | 34 | 0.110 |
Why?
| Diet | 1 | 2021 | 1198 | 0.110 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2016 | 510 | 0.110 |
Why?
| Dietary Fiber | 1 | 2014 | 49 | 0.110 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 5353 | 0.110 |
Why?
| Vitamin D Deficiency | 1 | 2015 | 176 | 0.100 |
Why?
| Hyperglycemia | 2 | 2014 | 326 | 0.100 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2019 | 563 | 0.100 |
Why?
| Oscillometry | 2 | 2011 | 37 | 0.100 |
Why?
| Exercise Therapy | 2 | 2015 | 412 | 0.100 |
Why?
| Regression Analysis | 2 | 2014 | 978 | 0.100 |
Why?
| Research | 1 | 2015 | 408 | 0.100 |
Why?
| Logistic Models | 2 | 2017 | 1975 | 0.100 |
Why?
| Infant | 5 | 2019 | 8912 | 0.100 |
Why?
| Mercury | 1 | 2012 | 39 | 0.100 |
Why?
| Hot Temperature | 1 | 2014 | 359 | 0.100 |
Why?
| Vitamin D | 1 | 2015 | 380 | 0.090 |
Why?
| Hemodynamics | 2 | 2018 | 1077 | 0.090 |
Why?
| Aortic Coarctation | 1 | 2012 | 82 | 0.090 |
Why?
| Louisiana | 4 | 2004 | 27 | 0.090 |
Why?
| Rhinitis | 1 | 2012 | 148 | 0.090 |
Why?
| Environmental Monitoring | 1 | 2013 | 314 | 0.090 |
Why?
| Pregnancy | 5 | 2024 | 6355 | 0.090 |
Why?
| Postoperative Complications | 2 | 2021 | 2456 | 0.090 |
Why?
| Gastroesophageal Reflux | 1 | 2012 | 230 | 0.090 |
Why?
| Child Welfare | 1 | 2012 | 211 | 0.080 |
Why?
| Uric Acid | 2 | 2024 | 160 | 0.080 |
Why?
| Allylamine | 1 | 2009 | 8 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2024 | 3009 | 0.080 |
Why?
| Motor Activity | 2 | 2014 | 667 | 0.080 |
Why?
| Skin | 1 | 2014 | 711 | 0.080 |
Why?
| Exercise Test | 1 | 2012 | 613 | 0.080 |
Why?
| Manometry | 1 | 2009 | 90 | 0.080 |
Why?
| Cluster Analysis | 1 | 2011 | 477 | 0.080 |
Why?
| Severity of Illness Index | 1 | 2017 | 2703 | 0.080 |
Why?
| Ultrasonography, Doppler | 1 | 2009 | 118 | 0.080 |
Why?
| Particulate Matter | 2 | 2021 | 245 | 0.070 |
Why?
| Statistics as Topic | 3 | 2004 | 303 | 0.070 |
Why?
| Leg | 1 | 2010 | 236 | 0.070 |
Why?
| Eating | 2 | 2021 | 368 | 0.070 |
Why?
| Combined Modality Therapy | 3 | 2020 | 1199 | 0.070 |
Why?
| Magnetic Resonance Angiography | 1 | 2009 | 235 | 0.070 |
Why?
| Health Surveys | 2 | 2020 | 491 | 0.070 |
Why?
| Neoplasms | 1 | 2021 | 2460 | 0.070 |
Why?
| Weight Loss | 2 | 2024 | 725 | 0.060 |
Why?
| C-Reactive Protein | 2 | 2019 | 396 | 0.060 |
Why?
| Fibrinogen | 2 | 2019 | 158 | 0.060 |
Why?
| Metformin | 2 | 2020 | 312 | 0.060 |
Why?
| Midwestern United States | 1 | 2024 | 41 | 0.060 |
Why?
| Treatment Outcome | 4 | 2019 | 10110 | 0.060 |
Why?
| Adipose Tissue | 1 | 2008 | 589 | 0.060 |
Why?
| Arterial Occlusive Diseases | 1 | 2004 | 79 | 0.050 |
Why?
| Bioprosthesis | 1 | 2003 | 39 | 0.050 |
Why?
| Nitric Oxide Synthase | 1 | 2004 | 230 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2019 | 662 | 0.050 |
Why?
| Ventricular Outflow Obstruction | 1 | 2003 | 40 | 0.050 |
Why?
| Arterial Pressure | 1 | 2023 | 116 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2020 | 1012 | 0.050 |
Why?
| Heart Valve Prosthesis | 1 | 2003 | 111 | 0.050 |
Why?
| Reward | 1 | 2024 | 237 | 0.050 |
Why?
| Body Constitution | 1 | 2002 | 53 | 0.050 |
Why?
| Renal Insufficiency, Chronic | 1 | 2008 | 562 | 0.050 |
Why?
| Heart Atria | 1 | 2022 | 127 | 0.050 |
Why?
| Iowa | 1 | 2021 | 24 | 0.050 |
Why?
| Ventricular Function | 1 | 2002 | 61 | 0.050 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2003 | 174 | 0.050 |
Why?
| Mendelian Randomization Analysis | 1 | 2021 | 46 | 0.050 |
Why?
| Gadolinium | 1 | 2021 | 77 | 0.050 |
Why?
| Venous Pressure | 1 | 2021 | 8 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2004 | 638 | 0.050 |
Why?
| Pregnancy Complications | 2 | 2019 | 487 | 0.040 |
Why?
| Intra-Abdominal Fat | 1 | 2021 | 88 | 0.040 |
Why?
| Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| Double-Blind Method | 2 | 2019 | 1852 | 0.040 |
Why?
| Stem Cell Transplantation | 1 | 2022 | 165 | 0.040 |
Why?
| United Kingdom | 1 | 2021 | 258 | 0.040 |
Why?
| Body Height | 1 | 2021 | 192 | 0.040 |
Why?
| Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 184 | 0.040 |
Why?
| Myocardial Contraction | 1 | 2002 | 333 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 285 | 0.040 |
Why?
| Echocardiography, Doppler | 1 | 2020 | 108 | 0.040 |
Why?
| Public Health | 1 | 2024 | 478 | 0.040 |
Why?
| Infant Health | 1 | 2019 | 24 | 0.040 |
Why?
| Croatia | 1 | 2019 | 5 | 0.040 |
Why?
| Organ Size | 1 | 2020 | 440 | 0.040 |
Why?
| Placebo Effect | 1 | 2019 | 55 | 0.040 |
Why?
| Intersectoral Collaboration | 1 | 2019 | 60 | 0.040 |
Why?
| Natriuretic Peptide, Brain | 1 | 2019 | 99 | 0.040 |
Why?
| Infertility | 1 | 2019 | 50 | 0.040 |
Why?
| Electrocardiography | 1 | 2022 | 607 | 0.040 |
Why?
| Research Support as Topic | 1 | 2019 | 111 | 0.040 |
Why?
| Contrast Media | 1 | 2021 | 387 | 0.040 |
Why?
| Education | 1 | 2019 | 100 | 0.040 |
Why?
| Risk Reduction Behavior | 1 | 2020 | 208 | 0.040 |
Why?
| Athletes | 1 | 2022 | 407 | 0.040 |
Why?
| Alabama | 1 | 2018 | 31 | 0.040 |
Why?
| Diabetic Retinopathy | 1 | 2020 | 172 | 0.040 |
Why?
| Carbon | 1 | 2019 | 207 | 0.040 |
Why?
| Child Health | 1 | 2019 | 146 | 0.040 |
Why?
| Child Behavior | 1 | 2020 | 235 | 0.040 |
Why?
| Transition to Adult Care | 1 | 2019 | 76 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 755 | 0.040 |
Why?
| New York City | 1 | 2017 | 80 | 0.040 |
Why?
| Congresses as Topic | 1 | 2019 | 211 | 0.040 |
Why?
| Guideline Adherence | 2 | 2012 | 523 | 0.030 |
Why?
| Oxygen | 1 | 2022 | 899 | 0.030 |
Why?
| Animals | 1 | 2019 | 34487 | 0.030 |
Why?
| Radial Artery | 1 | 2017 | 69 | 0.030 |
Why?
| Diabetic Nephropathies | 1 | 2020 | 278 | 0.030 |
Why?
| Europe | 1 | 2017 | 359 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2019 | 669 | 0.030 |
Why?
| Dilatation, Pathologic | 1 | 2016 | 60 | 0.030 |
Why?
| Body Surface Area | 1 | 2016 | 33 | 0.030 |
Why?
| Thrombosis | 1 | 2019 | 323 | 0.030 |
Why?
| Patient Education as Topic | 2 | 2011 | 733 | 0.030 |
Why?
| Terminology as Topic | 1 | 2017 | 199 | 0.030 |
Why?
| Interleukin-6 | 1 | 2019 | 712 | 0.030 |
Why?
| Fractures, Bone | 1 | 2020 | 393 | 0.030 |
Why?
| Videoconferencing | 1 | 2015 | 63 | 0.030 |
Why?
| Patient Selection | 1 | 2018 | 658 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2017 | 1194 | 0.030 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2009 | 410 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2018 | 1211 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 56 | 0.030 |
Why?
| Aged | 2 | 2024 | 21892 | 0.030 |
Why?
| Blood Cell Count | 1 | 2012 | 52 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 1264 | 0.030 |
Why?
| Internationality | 1 | 2013 | 149 | 0.020 |
Why?
| Liver | 1 | 2021 | 1826 | 0.020 |
Why?
| Dust | 1 | 2012 | 94 | 0.020 |
Why?
| Clinical Trials as Topic | 2 | 2007 | 997 | 0.020 |
Why?
| Analysis of Variance | 1 | 2015 | 1266 | 0.020 |
Why?
| Spirometry | 1 | 2012 | 252 | 0.020 |
Why?
| Headache | 1 | 2012 | 137 | 0.020 |
Why?
| Sex Characteristics | 1 | 2017 | 719 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1681 | 0.020 |
Why?
| Chronic Disease | 1 | 2017 | 1690 | 0.020 |
Why?
| Inservice Training | 1 | 2012 | 111 | 0.020 |
Why?
| Health Status | 1 | 2016 | 747 | 0.020 |
Why?
| Observer Variation | 1 | 2012 | 310 | 0.020 |
Why?
| Sound | 1 | 2011 | 67 | 0.020 |
Why?
| Circadian Rhythm | 1 | 2014 | 409 | 0.020 |
Why?
| Eosinophils | 1 | 2012 | 323 | 0.020 |
Why?
| Colesevelam Hydrochloride | 1 | 2009 | 8 | 0.020 |
Why?
| Electronic Health Records | 1 | 2017 | 973 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2021 | 7029 | 0.020 |
Why?
| Registries | 1 | 2017 | 1873 | 0.020 |
Why?
| Social Class | 1 | 2011 | 258 | 0.020 |
Why?
| Cost-Benefit Analysis | 1 | 2011 | 567 | 0.020 |
Why?
| Hyperlipoproteinemias | 1 | 2007 | 7 | 0.020 |
Why?
| Cholesterol, Dietary | 1 | 2007 | 18 | 0.020 |
Why?
| Contraindications | 1 | 2007 | 87 | 0.020 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 251 | 0.020 |
Why?
| Diet, Fat-Restricted | 1 | 2007 | 80 | 0.020 |
Why?
| HIV Protease Inhibitors | 1 | 2007 | 64 | 0.020 |
Why?
| Phytotherapy | 1 | 2007 | 79 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1943 | 0.020 |
Why?
| Dietary Fats | 1 | 2007 | 301 | 0.010 |
Why?
| Equipment Design | 1 | 2006 | 515 | 0.010 |
Why?
| Glomerular Filtration Rate | 1 | 2008 | 682 | 0.010 |
Why?
| Los Angeles | 1 | 2003 | 63 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2004 | 197 | 0.010 |
Why?
| Genetic Markers | 1 | 2004 | 338 | 0.010 |
Why?
| Gene Frequency | 1 | 2004 | 504 | 0.010 |
Why?
| Pulmonary Valve | 1 | 2003 | 93 | 0.010 |
Why?
| Alleles | 1 | 2004 | 842 | 0.010 |
Why?
| Aortic Valve | 1 | 2003 | 346 | 0.010 |
Why?
| Asthma | 1 | 2012 | 2212 | 0.010 |
Why?
| Genotype | 1 | 2004 | 1828 | 0.010 |
Why?
| Pulmonary Artery | 1 | 2003 | 1030 | 0.010 |
Why?
|
|
Urbina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|